Message #22 From:
Stock News Bot Date: November 28, 2006 06:00:00 AM
NPHC News Nutra Pharma Announces ReceptoPharm to Present at the International Conference on Neurotoxins
BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is
developing drugs for HIV and Multiple Sclerosis (MS) has announced today
that its holding, ReceptoPharm, has been invited to present its recent
analgesic research on RPI-78M at the International Conference on
Neurotoxins (ICoN) in Hollywood, Florida.
“It is exciting to be able to present the
results of our research at the 2006 ICoN meeting,”
commented Dr. Paul Reid, CEO of ReceptoPharm, Inc. “We
are planning to discuss our research and findings on the relief of pain
using our lead drug candidate, RPI-78M,” he
added.
In September 2006, Neuroscience Bulletin published the positive results
of a ReceptoPharm study on the use of RPI-78M for the relief of pain.
The study confirms that RPI-78M has analgesic activity and supports some
of the clinical reports of pain relief in subjects with herpes
infections and rheumatoid arthritis.
“The purpose of this study was to examine the
pain relieving effects of RPI-78M in laboratory rats and mice,”
explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “The
prolonged analgesic activity suggests that RPI-78M could be very useful
in combination with other analgesic agents currently in use,”
he concluded.
ReceptoPharm recently announced their approval by the British Medicines
and Healthcare products Regulatory Agency to begin Phase IIb human
trials with RPI-78M for the treatment of AMN (Adrenomyeloneuropathy).
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the
acquisition, licensing and commercialization of pharmaceutical products
and technologies for the management of neurological disorders, cancer,
autoimmune and infectious diseases. Nutra Pharma Corp. through its
subsidiaries carries out basic drug discovery research and clinical
development and also seeks strategic licensing partnerships to reduce
the risks associated with the drug development process. The Company's
holding, ReceptoPharm, Inc, is developing technologies for the
production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's
subsidiary, Designer Diagnostics is engaged in the research and
development of diagnostic test kits designed to be used for the rapid
identification of infectious diseases such as Tuberculosis (TB) and
Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to
identify and acquire intellectual property and companies in the
biotechnology arena.
This press release contains forward-looking statements. The words or
phrases "would be," "will allow," "intends to," "will likely result,"
"are expected to," "will continue," "is anticipated," "estimate,"
"project," or similar expressions are intended to identify
"forward-looking statements." Actual results could differ materially
from those projected in Nutra Pharma's ("the Company") business plan.
The Company's business is subject to various risks, which are discussed
in the Company's filings with the Securities and Exchange Commission
("SEC").The presentation at the ICoN meeting should
not be construed as an indication in any way whatsoever of the value of
the Company or its common stock.The Company's filings may be
accessed at the SEC's Edgar system at www.sec.gov.Statements made herein are as of the date of this press release and
should not be relied upon as of any subsequent date. The Company
cautions readers not to place reliance on such statements. Unless
otherwise required by applicable law, we do not undertake, and we
specifically disclaim any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.
